Potassium News and Research

RSS

Cardiac arrest due to medication-induced heart rhythm disturbance: Rare but catastrophic

Hospital care providers need to be more aware that cardiac arrest from a medication-induced heart rhythm problem is a rare but potentially catastrophic event in patients, according to a joint scientific statement from the American Heart Association and American College of Cardiology.

10 Feb 2010

Low potassium levels increase risk of death in patients with heart failure and CKD

New research from the University of Alabama at Birmingham (UAB) says low potassium levels produce an increased risk of death or hospitalization in patients with heart failure and chronic kidney disease (CKD).

10 Feb 2010

Low potassium levels increase risk of death in patients with heart failure and CKD

9 Feb 2010

Unhealthy behaviors contribute to excessive number of premature deaths in U.S.

The standard American diet, combined with inactivity and other unhealthy lifestyle behaviors, contributes to an excessive number of premature deaths in this country, according to leading preventive cardiology experts speaking at the American College of Cardiology's Fourth Annual Heart of Women's Health Conference in Washington, D.C.

9 Feb 2010

AMPYRA for MS: Acorda Therapeutics announces wholesale pricing and patient assistance program

Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.

3 Feb 2010

Two new studies further the understanding of molecular steps in PLC cascade

Two new studies by researchers at the University of Washington further our understanding of the molecular steps in the PLC cascade, a G protein-coupled receptor signaling mechanism that underlies a wide variety of cellular processes, including egg fertilization, hormone secretion, and the regulation of certain potassium channels.

27 Jan 2010

caprotec bioanalytics launches three new caproKits based on its CCMS technology

caprotec bioanalytics announced today the commercial launch of three new caproKits(TM), enabling the discovery, identification and characterization of proteins belonging to the groups of metallo-proteases, histon-deacetylases and GDP/GTP binding proteins.

27 Jan 2010

NPD Group names yogurt as food trend of the decade

Americans are eating more yogurt than ever before, and Dairy Council of California advises that consumers can benefit from even more culture.

25 Jan 2010

Elan Drug Technologies issues statement on FDA approval of AMPYRA

Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) today issued the following statement regarding the U.S. Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) as a treatment to improve walking in patients with multiple sclerosis (MS).

25 Jan 2010

Biogen Idec's statement on FDA approval of AMPYRA

Biogen Idec today issued the following statement regarding the United States (U.S.) Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) to improve walking in patients with multiple sclerosis (MS).

23 Jan 2010

FDA's Ampyra approval wonderful news for people with MS experiencing walking problems

The U.S. Food and Drug Administration has approved the marketing of Ampyra™ (dalfampridine, formerly known as fampridine SR, from Acorda Therapeutics) for its ability to improve walking speed in people with any type of multiple sclerosis.

23 Jan 2010

FDA approves fampridine-SR drug for treatment of multiple sclerosis

The Food and Drug Administration has approved the drug fampridine-SR for the treatment of multiple sclerosis. Researchers at the University of Rochester Medical Center (URMC) have been evaluating the effects of the drug in MS for more than 10 years- it is the first medication shown to enhance some neurological functions in people with the disease - and their efforts helped pave the way for today's action by the FDA.

23 Jan 2010

Acorda Therapeutics receives marketing approval from FDA for AMPYRA

Acorda Therapeutics, Inc. today announced that it has received marketing approval from the U.S. Food and Drug Administration (FDA) for AMPYRA™ (dalfampridine), an oral treatment to improve walking in patients with multiple sclerosis (MS).

22 Jan 2010

Most Americans knowledgeable about heart health, but do not exercise or maintain a healthy diet

A new survey of American adults revealed that while most feel knowledgeable when it comes to heart health, many do not put their knowledge into practice. In fact, 81 percent of respondents reported feeling well-informed about ways to maintain heart health and almost nine out of 10 knew they could help reduce the risk of heart disease by exercising and maintaining a healthy diet.

20 Jan 2010

Protein supplements do not improve athletes' performance

Protein supplements don't improve performance or recovery time and, according to a recent study, such supplements are inefficient for most athletes. "They are often poorly used or unnecessary by both high-level athletes and amateurs," says Martin Fr-chette, a researcher and graduate of the Universit- de Montr-al Department of Nutrition.

20 Jan 2010

Eating strategies can reduce cell damage and enhance sports performance

For a week Ms Gravina evaluated players from the first two Athletic teams (Superleague and National League), in order to observe their eating habits and where they could improve.

19 Jan 2010

First sulfite-free rectal suspension for UC

sfRowasa™ (mesalamine) Rectal Suspension 4g/60mL –Sulfite-Free Formulation, is the first sulfite-free rectal suspension available for Ulcerative colitis (UC). According to a study published in The American Journal of Gastroenterology, products containing sulfites may exacerbate natural sulfide levels in the colon and may increase inflammation in UC patients. With its sulfite-free preparation, sfRowasa™ offers a new treatment option for the treatment of active, mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis.

13 Jan 2010

Scientists identify gene underlying a disease that causes temporary paralysis of skeletal muscle

Scientists have identified a gene underlying a disease that causes temporary paralysis of skeletal muscle. The finding, they say, illustrates how investigations of rare genetic diseases can drive insights into more common ones.

8 Jan 2010

CLSI’s document provides revised guidelines for screening cystic fibrosis

Clinical and Laboratory Standards Institute (CLSI) recently published Sweat Testing: Sample Collection and Quantitative Chloride Analysis; Approved Guideline—Third Edition (C34-A3). This document addresses appropriate methods of collection and analysis, quality control, and the evaluation and reporting of sweat test results for the diagnosis of cystic fibrosis.

7 Jan 2010

ATP-sensitive potassium channel can contribute to fat deposition and obesity, new study says

A new study involving the University of Iowa, Mayo Clinic and two other institutions provides insight on weight control, suggesting that a ATP-sensitive potassium channel critical to survival and stress adaptation can contribute to fat deposition and obesity.

6 Jan 2010

Potassium News and Research

Cardiac arrest due to medication-induced heart rhythm disturbance: Rare but catastrophic

Low potassium levels increase risk of death in patients with heart failure and CKD

Low potassium levels increase risk of death in patients with heart failure and CKD

Unhealthy behaviors contribute to excessive number of premature deaths in U.S.

AMPYRA for MS: Acorda Therapeutics announces wholesale pricing and patient assistance program

Two new studies further the understanding of molecular steps in PLC cascade

caprotec bioanalytics launches three new caproKits based on its CCMS technology

NPD Group names yogurt as food trend of the decade

Elan Drug Technologies issues statement on FDA approval of AMPYRA

Biogen Idec's statement on FDA approval of AMPYRA

FDA's Ampyra approval wonderful news for people with MS experiencing walking problems

FDA approves fampridine-SR drug for treatment of multiple sclerosis

Acorda Therapeutics receives marketing approval from FDA for AMPYRA

Most Americans knowledgeable about heart health, but do not exercise or maintain a healthy diet

Protein supplements do not improve athletes' performance

Eating strategies can reduce cell damage and enhance sports performance

First sulfite-free rectal suspension for UC

Scientists identify gene underlying a disease that causes temporary paralysis of skeletal muscle

CLSI’s document provides revised guidelines for screening cystic fibrosis

ATP-sensitive potassium channel can contribute to fat deposition and obesity, new study says

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News